Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for our roundups of oil and gas and mining small caps.
Poolbeg Pharma
With multiple programmes moving through the trials process, rapidly evolving AI-led drugs discovery processes, and cash in hand, Poolbeg Pharma (AIM:POLB) is at a similar stage in its journey to another venture seeded by Cathal Friel’s Raglan Capital, Amyrt Pharma, sold earlier this year for $1.5bn. Those ambitions were confirmed last month with the appointment of senior executives who drove the Amryt deal to POLB’s leadership team.
POLB commercialises an extensive clinical data repository developed by another Raglan Capital enterprise, hVIVO, in the course of 20 years of challenge trials testing how the body’s immune system can be boosted to overcome viruses including SARS-CoV-2, influenza, RSV, and HRV.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
